News Channels

10 Oct 2017 Seattle Genetics and Astellas Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
10 Oct 2017 KalVista Pharmaceuticals Announces Collaboration with Merck
10 Oct 2017 Medicenna Presents Clinical Data on Initial Experience from Ongoing Phase 2b Study of MDNA55
10 Oct 2017 AbbVie and Turnstone Biologics Announce Global Collaboration on Viral Immunotherapies in Oncology
10 Oct 2017 Allergan Announces that the FDA Accepts New Drug Application for Ulipristal Acetate for Uterine Fibroids
10 Oct 2017 Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer
10 Oct 2017 AnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis
10 Oct 2017 Data Monitoring Committee Unanimously Recommends Continuation of Combioxin First-in-Human Clinical Trial with CAL02 in Patients with Severe Pneumococcal Pneumonia
10 Oct 2017 China Biologic Receives Approval for Commercial Manufacturing of Human Fibrinogen
10 Oct 2017 Evolus Announces Presentations of Phase II and Phase III Data of PrabotulinumtoxinA
10 Oct 2017 Entasis Therapeutics Highlights Positive Phase 1 Data for ETX2514 at IDWeek 2017, Announces Plans to Advance Combination with sulbactam (ETX2514SUL) into Phase 2 Trials
10 Oct 2017 Arsanis Presents Phase 1 and Preclinical Pharmacokinetic Data on Lead Product Candidate, ASN100, at IDWeek™ 2017
10 Oct 2017 Clovis Oncology Submits Supplemental New Drug Application for Rucaparib as Maintenance Treatment for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
10 Oct 2017 GNI Group Announces Clearance of Investigational New Drug (IND) by FDA for F351 Clinical Trials in the Treatment of Liver Fibrosis
10 Oct 2017 ERYTECH Announces Resubmission of European Marketing Authorization Application for GRASPA in Acute Lymphoblastic Leukemia
10 Oct 2017 OncoArendi Therapeutics to Begin the Phase 1 Clinical Evaluation of its Novel Class of Medicines
10 Oct 2017 Amplyx Pharmaceuticals Highlights Phase 1 APX001 Data at IDWeek 2017
10 Oct 2017 FDA Accepts Supplemental Biologics License Application For Prolia® (Denosumab) In Glucocorticoid-Induced Osteoporosis
10 Oct 2017 Nicox and pSivida Enter Strategic Collaboration Agreement to Develop Sustained Release Drug to Lower Intraocular Pressure in Patients with Glaucoma
09 Oct 2017 Mycenax Biotech Inc. announces TGA approval of phase I clinical trial authorization application for LusiNEX to treat autoimmune diseases

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing